Cargando…

A Review of Mesoporous Silica Nanoparticle Delivery Systems in Chemo-Based Combination Cancer Therapies

Chemotherapy is an important anti-tumor treatment in clinic to date, however, the effectiveness of traditional chemotherapy is limited by its poor selectivity, high systemic toxicity, and multidrug resistance. In recent years, mesoporous silica nanoparticles (MSNs) have become exciting drug delivery...

Descripción completa

Detalles Bibliográficos
Autores principales: Gao, Ying, Gao, Dongruo, Shen, Jie, Wang, Qiwen
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Frontiers Media S.A. 2020
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7732422/
https://www.ncbi.nlm.nih.gov/pubmed/33330389
http://dx.doi.org/10.3389/fchem.2020.598722
_version_ 1783622090707959808
author Gao, Ying
Gao, Dongruo
Shen, Jie
Wang, Qiwen
author_facet Gao, Ying
Gao, Dongruo
Shen, Jie
Wang, Qiwen
author_sort Gao, Ying
collection PubMed
description Chemotherapy is an important anti-tumor treatment in clinic to date, however, the effectiveness of traditional chemotherapy is limited by its poor selectivity, high systemic toxicity, and multidrug resistance. In recent years, mesoporous silica nanoparticles (MSNs) have become exciting drug delivery systems (DDS) due to their unique advantages, such as easy large-scale production, adjustable uniform pore size, large surface area and pore volumes. While mesoporous silica-based DDS can improve chemotherapy to a certain extent, when used in combination with other cancer therapies MSN based chemotherapy exhibits a synergistic effect, greatly improving therapeutic outcomes. In this review, we discuss the applications of MSN DDS for a diverse range of chemotherapeutic combination anti-tumor therapies, including phototherapy, gene therapy, immunotherapy and other less common modalities. Furthermore, we focus on the characteristics of each nanomaterial and the synergistic advantages of the combination therapies. Lastly, we examine the challenges and future prospects of MSN based chemotherapeutic combination therapies.
format Online
Article
Text
id pubmed-7732422
institution National Center for Biotechnology Information
language English
publishDate 2020
publisher Frontiers Media S.A.
record_format MEDLINE/PubMed
spelling pubmed-77324222020-12-15 A Review of Mesoporous Silica Nanoparticle Delivery Systems in Chemo-Based Combination Cancer Therapies Gao, Ying Gao, Dongruo Shen, Jie Wang, Qiwen Front Chem Chemistry Chemotherapy is an important anti-tumor treatment in clinic to date, however, the effectiveness of traditional chemotherapy is limited by its poor selectivity, high systemic toxicity, and multidrug resistance. In recent years, mesoporous silica nanoparticles (MSNs) have become exciting drug delivery systems (DDS) due to their unique advantages, such as easy large-scale production, adjustable uniform pore size, large surface area and pore volumes. While mesoporous silica-based DDS can improve chemotherapy to a certain extent, when used in combination with other cancer therapies MSN based chemotherapy exhibits a synergistic effect, greatly improving therapeutic outcomes. In this review, we discuss the applications of MSN DDS for a diverse range of chemotherapeutic combination anti-tumor therapies, including phototherapy, gene therapy, immunotherapy and other less common modalities. Furthermore, we focus on the characteristics of each nanomaterial and the synergistic advantages of the combination therapies. Lastly, we examine the challenges and future prospects of MSN based chemotherapeutic combination therapies. Frontiers Media S.A. 2020-11-24 /pmc/articles/PMC7732422/ /pubmed/33330389 http://dx.doi.org/10.3389/fchem.2020.598722 Text en Copyright © 2020 Gao, Gao, Shen and Wang. http://creativecommons.org/licenses/by/4.0/ This is an open-access article distributed under the terms of the Creative Commons Attribution License (CC BY). The use, distribution or reproduction in other forums is permitted, provided the original author(s) and the copyright owner(s) are credited and that the original publication in this journal is cited, in accordance with accepted academic practice. No use, distribution or reproduction is permitted which does not comply with these terms.
spellingShingle Chemistry
Gao, Ying
Gao, Dongruo
Shen, Jie
Wang, Qiwen
A Review of Mesoporous Silica Nanoparticle Delivery Systems in Chemo-Based Combination Cancer Therapies
title A Review of Mesoporous Silica Nanoparticle Delivery Systems in Chemo-Based Combination Cancer Therapies
title_full A Review of Mesoporous Silica Nanoparticle Delivery Systems in Chemo-Based Combination Cancer Therapies
title_fullStr A Review of Mesoporous Silica Nanoparticle Delivery Systems in Chemo-Based Combination Cancer Therapies
title_full_unstemmed A Review of Mesoporous Silica Nanoparticle Delivery Systems in Chemo-Based Combination Cancer Therapies
title_short A Review of Mesoporous Silica Nanoparticle Delivery Systems in Chemo-Based Combination Cancer Therapies
title_sort review of mesoporous silica nanoparticle delivery systems in chemo-based combination cancer therapies
topic Chemistry
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7732422/
https://www.ncbi.nlm.nih.gov/pubmed/33330389
http://dx.doi.org/10.3389/fchem.2020.598722
work_keys_str_mv AT gaoying areviewofmesoporoussilicananoparticledeliverysystemsinchemobasedcombinationcancertherapies
AT gaodongruo areviewofmesoporoussilicananoparticledeliverysystemsinchemobasedcombinationcancertherapies
AT shenjie areviewofmesoporoussilicananoparticledeliverysystemsinchemobasedcombinationcancertherapies
AT wangqiwen areviewofmesoporoussilicananoparticledeliverysystemsinchemobasedcombinationcancertherapies
AT gaoying reviewofmesoporoussilicananoparticledeliverysystemsinchemobasedcombinationcancertherapies
AT gaodongruo reviewofmesoporoussilicananoparticledeliverysystemsinchemobasedcombinationcancertherapies
AT shenjie reviewofmesoporoussilicananoparticledeliverysystemsinchemobasedcombinationcancertherapies
AT wangqiwen reviewofmesoporoussilicananoparticledeliverysystemsinchemobasedcombinationcancertherapies